Nasal glucocorticosteroids for the treatment of allergic rhinitis and chronic sinusitis originated in the 1960s and have been the drug of choice for all types of rhinitis for half a century. The 2010 ARIA guidelines also give a high recommendation for nasal glucocorticosteroids, which also applies to pediatric patients. In our guidelines for the diagnosis and treatment of allergic rhinitis and chronic sinusitis, nasal glucocorticosteroids are also listed as one of the drugs of choice for treatment. Studies have shown that nasal glucocorticosteroids can effectively relieve the nasal symptoms of patients with allergic rhinitis and chronic sinusitis, and can also effectively control the total symptoms of all types of rhinitis in children. Nasal glucocorticosteroids also reduce ocular symptoms in patients with allergic rhinitis and are thought to be associated with suppression of the naso-ocular reflex. However, the main concern of both physicians and patients regarding the safety of nasal glucocorticosteroids is whether they may cause suppression of hypothalamic-pituitary-adrenal function or affect growth and development after long-term use. Current studies suggest that the commonly used nasal glucocorticosteroids in clinical practice are well tolerated in both adults and children. Some reports showed that adult patients using nasal glucocorticoids for 1 year did not have significantly different blood glucocorticoid levels compared with those before treatment; investigations of children using nasal glucocorticoids also showed that their height did not differ from that of normal children after 1 year of continuous use, and some reports even found that children’s height was slightly higher than that of the control group after 1 year of use, which was thought to be the result of improved nasal ventilation. Therefore, the current study suggests that nasal glucocorticoids are safe.